SCHEMBL3966087

SCHEMBL3966087

CC(=O)Nc1ccc(S(=O)(=O)NCc2cc3c(ccc4cnn(C[C@H](C)N)c43)o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.57
HTR2A P28223 5/20 0.57
HTR2B P41595 1/20 0.57
MAPT P10636 2/20 0.40
POLB P06746 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3965557 0.76 HTR2C (0.69) HTR2CHTR2AHTR2B
SCHEMBL6255885 0.76 ALDH1A1 (0.42) MAPTPOLBALDH1A1LMNAKDM4E
SCHEMBL3961833 0.75 HTR2C (0.80) HTR2CHTR2AHTR2B
SCHEMBL14521175 0.74 HTR2C (1.00) HTR2CHTR2AHTR2B
SCHEMBL3957133 0.72 HTR2C (0.71) HTR2CHTR2AHTR2BMAPTKDM4E
SCHEMBL3965543 0.72 HTR2C (0.67) HTR2CHTR2AHTR2B
Fumaric Acid SCHEMBL6195915 0.68 HTR2C (0.81) HTR2CHTR2AHTR2B
Fumaric Acid SCHEMBL3962476 0.65 HTR2C (0.60) HTR2CHTR2AHTR2B
SCHEMBL3966100 0.65 MMP2 (0.42) MAPTPOLBALDH1A1LMNAKDM4E
SCHEMBL3966091 0.65 MMP2 (0.42) MAPTPOLBALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476687-B2 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2009-01-13 US disclosed
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2009-01-08 US disclosed
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma ALCON, INC. (CH) 2007-06-14 US disclosed
WO-2005053688-A1 SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135430-A1 Substituted furo[2,3-g]indazoles for the treatment of glaucoma PTGIS, PTGIR, PTGS2 HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885
US-20090012291-A1 SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA PTGIS, PTGIR, PTGS2 HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.